FDA Recall of Prazosin Hydrochloride Capsules by Biocon Pharma
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Appco Pharma LLC is voluntarily recalling 28,157 bottles of Prazosin Hydrochloride Capsules due to detected impurities above acceptable limits, affecting nationwide distribution in the U.S.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 14, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, Drugs) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
Recall of Prazosin Hydrochloride Capsules
What Happened
Appco Pharma LLC is initiating a voluntary recall of the affected drug due to a cGMP deviation involving the detection of Nitrosamine Drug Substance-Related Impurities, specifically N-nitroso-prazosin impurity C (NNP), above acceptable limits.
Which Products Are Affected
The recall involves Prazosin Hydrochloride Capsules, USP, 5mg, in 100-count bottles. The affected NDCs are 70377-066, 70377-067, and 70377-068, with package NDCs including 70377-066-11, 70377-067-11, and 70377-068-11. A total of 28,157 bottles are affected, distributed nationwide in the U.S. The specific lots are: 2406255UC (Exp. 2026/MAY), 2406256UC (Exp. 2026/JUL), 2407313UC (Exp. 2026/JUL), 2408351UC (Exp. 2026/JUL), 2408352UC (Exp. 2026/JUL), and 2509311UC (Exp. 2027/SEP). The product is manufactured for Biocon Pharma Inc. and by Appco Pharma LLC, with recall number D-0421-2026.
What You Should Do
Consumers who have the affected lots of Prazosin Hydrochloride Capsules should follow the initial firm notification via e-mail and contact Appco Pharma LLC for instructions on returns or refunds. The recalling firm is located at 262 Old New Brunswick Rd Ste N, Piscataway, NJ 08854-3888.
Why This Matters
This recall highlights potential safety concerns in prescription drugs due to impurities, affecting thousands of bottles distributed across the United States and emphasizing the importance of quality control in pharmaceuticals.
Source
FDA recall notice for event ID 98658, available at the FDA website under recall number D-0421-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.